Medical Research Journals

MedicalResearch.com Interview with: [caption id="attachment_57288" align="alignleft" width="150"]David J. Durgan, PhD Department of Anesthesiology Baylor College of Medicine Houston, TX Dr. Durgan[/caption] David J. Durgan, PhD Department of Anesthesiology Baylor College of Medicine Houston, TX  MedicalResearch.com: What is the background for this study? Response: Our lab and others had previously shown that gut dysbiosis is not only associated with hypertension, but actually plays a causal role. For example we have shown in both a genetic model of hypertension as well as an obstructive sleep apnea induced model of hypertension, that transplantation of their dysbiotic microbiota into normotensive recipients induced elevations in blood pressure. With this understanding our focus shifted to two new questions 1) How can we manipulate the microbiota to improve/prevent hypertension, and 2) What are the signals originating from the microbiota that have the capability to influence host blood pressure? These questions lead to the experimental design of this study.

MedicalResearch.com Interview with: [caption id="attachment_57250" align="alignleft" width="200"]Anthony Almazan MD Candidate Harvard Medical School Anthony Almazan[/caption] Anthony Almazan MD Candidate Harvard Medical School MedicalResearch.com: What is the background for this study? Response: Gender-affirming surgeries are procedures offered to alleviate psychological distress and affirm the gender identities of transgender and gender diverse (TGD) people. Requests for these surgeries have been increasing in the United States over the past decade. However, the mental health benefits of these procedures have remained controversial due to the limited evidence base on this subject.

MedicalResearch.com Interview with: [caption id="attachment_57270" align="alignleft" width="176"]Yun Liu, PhD Google Health Palo Alto, California Dr. Yun Liu[/caption] Yun Liu, PhD Google Health Palo Alto, California MedicalResearch.com: What is the background for this study? Would you describe the system?  Does it use dermatoscopic images? Response: Dermatologic conditions are extremely common and a leading cause of morbidity worldwide. Due to limited access to dermatologists, patients often first seek help from non-specialists. However, non-specialists have been reported to have lower diagnostic accuracies compared to dermatologists, which may impact the quality of care. In this study, we built upon prior work published in Nature Medicine, where we developed a computer algorithm (a deep learning system, DLS) to interpret de-identified clinical images of skin conditions and associated medical history (such as whether the patient reported a history of psoriasis). These clinical images are taken using consumer-grade hardware such as point-and-shoot cameras and tablets, which we felt was a more accessible and widely-available device compared to dermatoscopes. Given such images of the skin condition as input, the DLS outputs a differential diagnosis, which is a rank-ordered list of potential matching skin conditions. In this paper, we worked with user experience researchers to create an artificial intelligence (AI) tool based on this DLS. The tool was designed to provide clinicians with additional information per skin condition prediction, such as textual descriptions, similar-appearing conditions, and the typical clinical workup for the condition. We then conducted a randomized study where 40 clinicians (20 primary care physicians, 20 nurse practitioners) reviewed over 1,000 cases -- with half the cases with the AI-based assistive tool, and half the cases without. For each case, the reference diagnosis was based on a panel of 3 dermatologists. 

MedicalResearch.com Interview with: [caption id="attachment_57254" align="alignleft" width="200"]Prof. Kristian Reich, MD, PhD Professor for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg-Eppendorf Prof. Reich[/caption] Prof. Kristian Reich, MD, PhD Professor for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg-Eppendorf MedicalResearch.com: What is the background for this study? What are the main findings? Response: Complete skin clearance is an important treatment goal for patients with psoriasis and is closely associated with treatment satisfaction and improved quality of life. However, it remains an unmet need for many patients. The interleukin (IL)-17 isoforms IL-17A and IL-17F play central roles in psoriasis pathophysiology and are overexpressed in psoriatic tissues. Existing biologic therapies, such as secukinumab, inhibit IL-17A only. However, increasing evidence indicates that IL-17F contributes independently to the pathobiology of plaque psoriasis, and that blocking both IL-17A and IL-17F may lead to more complete suppression of inflammation and superior clinical outcomes, compared with blocking IL‑17A alone. Bimekizumab is a humanized monoclonal IgG1 antibody that has been designed to selectively inhibit IL-17F in addition to IL-17A.

MedicalResearch.com Interview with: Michelle M. Chen, MD/MHS Clinical Lecturer Department of Otolaryngology-Head and Neck Surgery University of Michigan MedicalResearch.com: What is the background for this study? Response: HPV is the most common sexually transmitted infection in the United States and associated with several malignancies including oropharyngeal, cervical, vaginal, vulvar, penile, and anal cancers. In 2020, the FDA expanded the indications for HPV vaccination to include the prevention of oropharyngeal cancer, which is the most common HPV-associated malignancy and about 80% of oropharyngeal cancer patients are male. HPV vaccination rates are closely tracked for adolescents but less is known about vaccination rates for young adults. The goal of our study was to understand HPV vaccinations for young adult men and women, ages 18-21. 

MedicalResearch.com Interview with: [caption id="attachment_57214" align="alignleft" width="200"]Prof. Papageorghiou Prof. Papageorghiou[/caption] Aris Papageorghiou MBChB, MRCOG Professor of Fetal Medicine and the Clinical Research Director Oxford Maternal and Perinatal Health Institute University of Oxford MedicalResearch.com: What is the background for this study? Response: Our study was really guided by a key question: does Covid-19 in pregnancy increase the risk of adverse maternal and neonatal outcomes as compared with pregnant women who do not have the infection? The question is highly relevant because of the known deleterious effects of other coronavirus infections in pregnancy, e.g. SARS (severe acute respiratory syndrome) and MERS-CoV (Middle East respiratory syndrome coronavirus). In order to answer this question we undertook this multinational cohort study.

MedicalResearch.com Interview with: [caption id="attachment_57231" align="alignleft" width="142"]Joel N. Blankson, MD, PhD Department of Infectious Diseases Associate Professor Cellular and Molecular Medicine Program Johns Hopkins Dr. Blankson[/caption] Joel N. Blankson, MD, PhD Department of Infectious Diseases Associate Professor Cellular and Molecular Medicine Program Johns Hopkins MedicalResearch.com: What is the background for this study? Which vaccines did you evaluate? Response: Prior studies from several groups including our own have found T cell cross-recognition of peptides from SARS-CoV-2 and the common cold coronaviruses. We asked whether as a result of this cross-reactivity, immunization with the SARS-CoV-2 vaccine would also enhance T cell responses to the common cold coronaviruses. Prior studies also suggested that antibodies elicited from the mRNA vaccines had a reduced ability to neutralize the emerging variants of concern. Most of the study participants had received the Pfizer vaccine, but a few had received the Moderna vaccine. 

MedicalResearch.com Interview with: [caption id="attachment_54101" align="alignleft" width="133"]Dr. Michael Silverstein M.D., M.P.H Professor of Pediatrics Director of the Division of General Academic Pediatrics Vice Chair of Research, Department of Pediatrics Boston University School of Medicin Dr. Silverstein[/caption] Dr. Michael Silverstein M.D., M.P.H Professor of Pediatrics Director of the Division of General Academic Pediatrics Vice Chair of Research, Department of Pediatrics Boston University School of Medicine   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Vitamin D is an important nutrient for keeping bones healthy, and it may also have a role in other aspects of good health. However, we do not have enough evidence to understand what levels of vitamin D people need to keep them healthy or what levels are too low. As a result, the Task Force determined there is not enough evidence to recommend for or against screening for vitamin D deficiency in adults who do not have signs or symptoms. It is our hope that with more research, we will be able to make a strong, evidence-based recommendation on screening for vitamin D deficiency in the future.

MedicalResearch.com Interview with: First Author [caption id="attachment_57208" align="alignleft" width="150"]Michelle Lee, MD, PharmD Fellow-in-training, Health Services Research & Development Michael E. DeBakey VA Medical Center, Houston, TX Dr. Lee[/caption] Michelle Lee, MD, PharmD Fellow-in-training, Health Services Research & Development Michael E. DeBakey VA Medical Center, Houston, TX   [caption id="attachment_57209" align="alignleft" width="128"]Dr-Virani Dr. Virani[/caption] Senior & Corresponding Author Salim S. Virani, MD, PhD, FACC, FAHA, FASPC Professor, Section of Cardiovascular Research Director, Cardiology Fellowship Training Program Baylor College of Medicine Staff Cardiologist, Michael E. DeBakey Veterans Affairs Medical Center Co-Director, VA Advanced Fellowship in Health Services Research & Development Michael E. DeBakey VA Medical Center, Houston, TX Investigator, Health Policy, Quality and Informatics Program Michael E. DeBakey Veterans Affairs Medical Center HSR&D Center of Innovation Houston, TX MedicalResearch.com: What is the background for this study? Response: Atherosclerotic cardiovascular disease (ASCVD), defined as ischemic heart disease (IHD), ischemic cerebrovascular disease (ICVD), or peripheral arterial disease (PAD), is the leading cause of death globally. Particularly in young ASCVD patients, secondary prevention with antiplatelet therapy and statins are extremely important in reducing disease burden.

MedicalResearch.com Interview with: Aditya Bardia MD, MPH Director, Breast Cancer Research Program, Attending Physician, Massachusetts General Hospital Harvard Medical School [caption id="attachment_57202" align="alignleft" width="200"]Aditya Bardia MD, MPH Director, Breast Cancer Research Program, Attending Physician, Massachusetts General Hospital Harvard Medical School Dr. Bardia[/caption]  MedicalResearch.com: What is the background for this study? Response: Triple negative breast cancer (TNBC) represents an aggressive subtype of breast cancer associated with guarded prognosis. For patients with pre-treated metastatic TNBC, standard chemotherapy is associated with low response rate (5-10%) and poor progression-free survival (2-3 months), highlighting need for better therapies. Sacituzumab govitecan is an antibody drug conjugate (ADC) which  combines SN-38, an active metabolite of irinotecan, with an antibody against Trop-2, an antigen overexpressed in majority of triple negative breast cancer.

MedicalResearch.com Interview with: [caption id="attachment_57196" align="alignleft" width="200"]Efrat Monsonego Ornan, Ph.D  Head of School of Nutritional Sciences Institute of Biochemistry and Nutrition  The Robert H. Smith Faculty of Agriculture,  Food and Environment  The Hebrew University of Jerusalem Prof. Monsonego Ornan[/caption] Efrat Monsonego Ornan, Ph.D  Head of School of Nutritional Sciences Institute of Biochemistry and Nutrition The Robert H. Smith Faculty of Agriculture, Food and Environment The Hebrew University of Jerusalem MedicalResearch.com: What is the background for this study? Response: Food supplies in recent decades have been dominated by heavily processed, ready-to-eat products. Essentially, 75% of all world food sales are of processed foods. Over the past 30 years, children’s ultra-processed food intake has increased markedly, with 50% of the children in the US consuming these foods. Only in the US does UPF comprise 58% of energy intake, of which 90% is derived from added sugars. This reflects children’s excessive consumption of food and drink that are high in fat and refined sugars but do not provide appropriate levels of the proteins, vitamins and minerals required for growth. The negative health outcomes of excessive consumption of Ultra-processed food are well known, include obesity, metabolic syndrome and diabetes, and considered as the current world epidemic; the fact that children, during their postnatal development period (birth to adolescent), are the target of the Ultra-processed food industry is very disturbing in terms of public health. Bone development and growth are the characteristic phenomena of the childhood period. Yet, in spite of the huge importance of nutrition to bone development, the impact of Ultra-processed food consumption on skeleton development during childhood has never been studied directly, and this was the purpose of our study. To this end, we used young rats which are an excellent pre-clinical model for growth and fed them with either the recommended diet for their age or  a diet comprised of a typical Ultra-processed meal (a roll, hamburger, tomatoes, lettuce, ketchup and French fries) and a caloric soft drink.  

MedicalResearch.com Interview with: [caption id="attachment_57184" align="alignleft" width="200"]Eugenia McPeek Hinz MD MS FAMIA Associate CMIO - DHTS Duke University Health System Dr. McPeek Hinz[/caption] Eugenia McPeek Hinz MD MS FAMIA Associate CMIO - DHTS Duke University Health System MedicalResearch.com: What is the background for this study? Response: Clinician burnout rates have hovered around 50% for much of the past decade.  Burnout is a significant concern in healthcare for its effects on care givers and associated downstream adverse implications on patient care for quality and safety. The ubiquitous presence of Electronic Health Records (EHR) along with the increased clerical components and after hours use has been a significant concern for contributing to provider burnout. 

MedicalResearch.com Interview with: [caption id="attachment_57153" align="alignleft" width="163"]Emily Sickbert-Bennett PhD, MS, CIC, FSHEA Director, Infection Prevention, UNC Hospitals Administrative Director, Carolina Antimicrobial Stewardship Program, UNC Hospitals Associate Professor of Medicine-Infectious Diseases, UNC School of Medicine Associate Professor of Epidemiology, UNC Gillings School of Global Public Health Dr. Sickbert-Bennett[/caption] Emily Sickbert-Bennett PhD, MS, CIC, FSHEA Director, Infection Prevention, UNC Hospitals Administrative Director, Carolina Antimicrobial Stewardship Program, UNC Hospitals Associate Professor of Medicine-Infectious Diseases, UNC School of Medicine Associate Professor of Epidemiology, UNC Gillings School of Global Public Health MedicalResearch.com: What is the background for this study? Response: Recently public health officials have recommended doubling masks, although the initial study conducted by CDC investigators  was limited in type and combinations of masks tested, so our study compared fitted filtration efficiency of commonly available masks worn, singly, doubled or in combination. MedicalResearch.com: What are the main findings? Response:  Doubling of masks can improve the fitted filtration efficiency of masks, that is how well masks protect you from inhalation of aerosols from others. 

MedicalResearch.com Interview with: Duke Appiah, Ph.D., MPH Assistant Professor,Public Health Texas Tech University  MedicalResearch.com: What is the background for this study? Response: Reports from several countries point towards increasing trends in age at natural menopause. However, epidemiological report from the United States on the long-term trends in age at natural menopause or reproductive life span among a nationally representative sample of women is lacking. Understanding changes in the timing of age at natural menopause and length of the reproductive life span and their associated factors are important. For instance, earlier age at natural menopause is reported to be associated with cardiovascular diseases, neurological diseases and osteoporosis while later onset of menopause has been associated with the occurrence of breast, endometrial, and ovarian cancers. Similarly, longer durations of reproductive life span are associated with reduced morbidity and mortality.

MedicalResearch.com Interview with: [caption id="attachment_56968" align="alignleft" width="128"]Martin J Holzmann MD PhD Department of Emergency Medicine Karolinska University Hospital Stockholm, Sweden Dr. Holzmann[/caption] Martin J Holzmann MD PhD Department of Emergency Medicine Karolinska University Hospital Stockholm, Sweden  MedicalResearch.com: What is the background for this study? What are the main findings? Response: ​We published a paper 2007 in Heart where we showed that PDE5i lower mortality in men with a recent myocardial infarction. With this study we wanted to investigate if PDE5i led to a beneficial outcome in men with stable coronary artery disease.

MedicalResearch.com Interview with: [caption id="attachment_57068" align="alignleft" width="200"]Sarah Windle Sarah Windle[/caption] Sarah Windle, MPH PhD Student in Epidemiology Department of Epidemiology, Biostatistics, and Occupational Health McGill University (Montréal, Québec, Canada) MedicalResearch.com: What is the background for this study? Response: Concerns have been raised about the potential for increases in impaired driving following the legalization of recreational cannabis use in Canada in October 2018. Data from Statistics Canada suggest that cannabis use in the previous three months increased among adults (15 and older) from 14% before legalization in 2018 to 17% in 2019. Among those users with a driver’s license, 13% reported driving within two hours of cannabis use. While this proportion remained the same before and after legalization, this indicates that the absolute number of individuals who reported driving within two hours of use has increased following legalization (due to an increase in the number of users).

MedicalResearch.com Interview with: [caption id="attachment_57053" align="alignleft" width="133"]Chien-Wen Tseng, M.D., M.P.H., M.S.E.E. The Hawaii Medical Service Association Endowed Chair Health Services and Quality Research Professor, and Associate Research Director Department of Family Medicine and Community Health University of Hawaii John A. Burns School of Medicine Dr. Chien-Wen Tseng[/caption] Chien-Wen Tseng, M.D., M.P.H., M.S.E.E. The Hawaii Medical Service Association Endowed Chair Health Services and Quality Research Professor, and Associate Research Director Department of Family Medicine and Community Health University of Hawaii John A. Burns School of Medicine MedicalResearch.com: What is the background for this study? What are the main findings? Response: Age-related hearing loss cannot be reversed and can be a significant problem for older adults. Four out of 10 adults who are age 70 and older report hearing loss and it can worsen isolation, cognitive decline, and quality of life, as well as interfere with someone’s ability to live independently. There are simple screening tests to detect hearing loss, so the Task Force did an extensive review of whether there are health benefits to screening for hearing loss in people who do not have symptoms before they notice any hearing problems. The Task Force determined that there is not enough evidence to recommend for or against screening for hearing loss in adults who are age 50 and older and do not have signs or symptoms of hearing loss. This is an I statement.

MedicalResearch.com Interview with: [caption id="attachment_57046" align="alignleft" width="200"]Francesco D’Aiuto Professor/Hon Consultant Head of Periodontology Unit UCL Eastman Dental Institute Prof. D'Aiuto[/caption] Francesco D’Aiuto Professor/Hon Consultant Head of Periodontology Unit UCL Eastman Dental Institute  MedicalResearch.com: What is the background for this study? Response: This study was set out to further our understanding of the link between gum disease and high blood pressure. Recent evidence suggested that individuals with gum disease had a 20-70% increased risk of hypertension and systemic inflammation seemed to be a driver in mediating this association. Further research on the matter was needed. We recruited two relatively large groups of otherwise healthy participants (without a confirmed diagnosis of hypertension) who had gum disease one and healthy gums the other. We found that diagnosis of periodontitis (gum disease) was consistently linked to higher systolic blood pressure independent of other cardiovascular risk factors.

MedicalResearch.com Interview with: [caption id="attachment_57013" align="alignleft" width="180"]David C. Rettew, MD Child & Adolescent Psychiatrist Associate Professor of Psychiatry and Pediatrics University of Vermont Larner College of Medicine Dr. Rettew[/caption] David C. Rettew, MD Child & Adolescent Psychiatrist Associate Professor of Psychiatry and Pediatrics University of Vermont Larner College of Medicine MedicalResearch.com: What is the background for this study? Response: Our group, the Wellness Environment Scientific Team at the University of Vermont, hadn’t planned to look at COVID at the outset of this study and instead were going to look at mental health and engagement in wellness activities in college students across a semester. The pandemic disrupted that plan when students were abruptly sent home but fortunately, they continued to do their daily app-based ratings of their mood, stress levels, and engagement in healthy activities.  We then realized we had some interesting pre-COVID to COVID data that was worth exploring. 

MedicalResearch.com Interview with: [caption id="attachment_57001" align="alignleft" width="150"]Patrick DeMartino MD Pediatric Hematology and Oncology Fellow Doernbecher Children's Hospital Oregon Health & Science University Dr. DeMartino[/caption] Patrick DeMartino MD Pediatric Hematology and Oncology Fellow Doernbecher Children's Hospital Oregon Health & Science University MedicalResearch.com: What is the background for this study? Response: Dozens of gene therapies are expected to be on the market within a decade or so. Much has been written about the high prices of the therapies currently on the market (exceeding $1 million). However, only a small number of patients are eligible for these existing therapies each year. Gene therapy for sickle cell disease (SCD) appears promising and would potentially apply to a relatively large number of individuals in the U.S. We sought to explore potential affordability challenges associated with a gene therapy for SCD.

MedicalResearch.com Interview with: [caption id="attachment_56997" align="alignleft" width="181"]Nathalie Auger Professeure agrégée de clinique École de santé publique - Département de médecine sociale et preventive University of Montreal Prof.Auger[/caption] Nathalie Auger Professeure agrégée de clinique École de santé publique - Département de médecine sociale et preventive University of Montreal MedicalResearch.com: What is the background for this study? Response: COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been a major public health concern. The number of infected pregnant women continues to increase. Pregnant women and infants are particularly susceptible to COVID-19 because the physiologic changes of pregnancy involve cardiovascular, respiratory, and immune changes that may alter the response to SARS-CoV-2 infection. Fetuses may be exposed to SARS-CoV-2 during critical periods of development. The nature of the association between COVID-19 and pregnancy outcomes remains unclear and meta-analyses of pregnant women with COVID-19 are lacking.

MedicalResearch.com Interview with: Sungchul Park, MPH PhD Assistant Professor, Health Management and Policy Dornsife School of Public Health Drexel University Philadelphia, PA 19104Sungchul Park, MPH PhD Assistant Professor, Health Management and Policy Dornsife School of Public Health Drexel University Philadelphia, PA 19104   MedicalResearch.com: What is the background for this study? Response: Evidence suggests that a significant share of health care costs in the US is of low value. In some cases, low-value care can be associated with harmful patient outcomes. Thus, decreasing use of low-value care is a major goal for Medicare given the potential to decrease costs and harms. Compared with traditional fee-for-service Medicare (TM), Medicare Advantage (MA) is more strongly financially incentivized to decrease use of low-value care.

MedicalResearch.com Interview with: Chao Cao, MPH PhD student in Movement Science, Program in Physical Therapy, Washington University School of Medicine. Senior author: Lin Yang, PhD Research Scientist/Epidemiologist Department of Cancer Epidemiology and Prevention Research Cancer Care Alberta | Alberta Health Services | Canada MedicalResearch.com: What is the background for this study? dizziness-vertigoResponse: Dizziness and imbalance are common among US adults and increases the risk of serious injuries. However, research related to balance overwhelmingly focuses on functional outcomes among older adults, therefore our understanding on how balance function may affect the long-term health outcomes in adults of different age group is limited. MedicalResearch.com: What are the main findings?  Response: We found that balance disorder affects nearly 2/3 of older Americans (65+ yr) as well as 1/3 of those middle-aged (50-64 yr). Our study, for the first time, found that for middle-aged and older Americans, their overall and sensory-specific balance disorders (visual, proprioceptive, and vestibular) were associated with higher mortality risks driven by cancer and CVD death over 12 years.  

MedicalResearch.com Interview with: [caption id="attachment_56988" align="alignleft" width="200"]matt-spick Matt Spick[/caption] Matt Spick, Post-Graduate Researcher University of Surrey Faculty of Engineering and Physical Sciences Guildford, UK MedicalResearch.com: What is the background for this study? Are you measuring lipids or the virus? Response: In this study, we aimed to detect what the virus does to us, rather than the virus itself. The gold standard for detecting COVID-19 is the RT-PCR test, but by their nature, PCR tests only provide diagnostic information, and at times during the pandemic the availability of PCR tests has been a bottleneck for the identification of the disease. Our goal was to investigate a novel method for the diagnosis of COVID-19, at the same time as learning more about what the disease does to us through lipidomics.

MedicalResearch.com Interview with: [caption id="attachment_56972" align="alignleft" width="180"]Anne Cust | Professor of Cancer Epidemiology The University of Sydney Faculty of Medicine and Health Sydney School of Public Health Anne Cust[/caption] Anne Cust | PhD, Professor of Cancer Epidemiology The University of Sydney Faculty of Medicine and Health Sydney School of Public Health MedicalResearch.com: What is the background for this study? Are the screeners specially trained, use full body photographs, dermoscopy etc? Response: The Melanoma High-risk Clinic Study was developed to optimise the early detection of new melanomas in people at high risk of developing melanoma. A previous single-centre study observed fewer excisions and healthcare costs, thinner melanomas and better quality of life when surveillance of high risk patients was conducted in a melanoma dermatology clinic with a structured surveillance protocol involving 6-monthly full body examinations aided by total body photography (TBP) and sequential digital dermoscopy imaging (SDDI). The initial pilot study was performed in a single tertiary referral specialist centre using trained dermatologists who routinely used the diagnostic interventions. Our objective was to examine longer-term sustainability and expansion of the program to multiple practices including a primary care skin cancer clinic setting. The hypothesis was that the outcomes would be similar if using the same protocol and diagnostic tools. The participating doctors were trained to follow the protocol, which included instruction on how to respond and interpret changing lesions, but not in use of dermoscopy or skin examinations, which were routinely and consistently used in all clinics prior to the study commencing. There were 593 participants assessed as very high risk of melanoma who participated in the Melanoma High-risk Clinic Study from 2012-2018. Nearly all of the participants had had a previous melanoma and had additional melanoma risk factors. 57% were male and the median age at study entry was 58 years.

MedicalResearch.com Interview with: [caption id="attachment_56962" align="alignleft" width="133"]MedicalResearch.com Interview with: John B. Wong, M.D. Chief Scientific Officer, Vice Chair for Clinical Affairs Chief of the Division of Clinical Decision Making Primary Care Clinician Department of Medicine Tufts Medical Center Dr. Wong[/caption] John B. Wong, M.D. Chief Scientific Officer, Vice Chair for Clinical Affairs Chief of the Division of Clinical Decision Making Primary Care Clinician Department of Medicine Tufts Medical Center  MedicalResearch.com: What is the background for this study? Response: Lung cancer is the leading cause of cancer death for both men and women in the United States. More than 200,000 people are diagnosed with this devastating disease each year. Smoking is the leading cause of lung cancer, resulting in the vast majority of lung cancers in the United States.

MedicalResearch.com Interview with: [caption id="attachment_56959" align="alignleft" width="200"]Stephen Salloway, M.D., M.S. Director of Neurology and the Memory and Aging Program, Butler Hospital Martin M. Zucker Professor of Psychiatry and Human Behavior Professor of Neurology, Alpert Medical School of Brown University Providence, RI 02906  Dr. Salloway[/caption] Stephen Salloway, M.D., M.S. Director of Neurology and the Memory and Aging Program, Butler Hospital Martin M. Zucker Professor of Psychiatry and Human Behavior Professor of Neurology, Alpert Medical School of Brown University Providence, RI 02906  MedicalResearch.com: What is the background for this study? Response: This 78 week phase 2 study tested donanemab in patients with early Alzheimer’s disease. Donanemab is a an anti-amyloid monoclonal antibody that targets the N3 pyroglutamate epitope.  MedicalResearch.com: What are the main findings? Response: The drug produced a substantial lowering of amyloid plaques and showed a slowing in cognitive decline. Key innovations included using PET scans to ensure all patients were amyloid positive and had a moderate level of tau build-up and switching from drug to placebo once the amyloid level was below the expected cut-off for Alzheimer’s disease. There were no new safety signals. The main side-effect was amyloid-related imaging abnormalities (ARIA) that have been seen with other anti-amyloid treatments. ARIA is managed with regular safety MRI scans.  Donanemab is now being tested in a larger phase 3 trial that could lead to regulatory approval.